Director, Research & Development Division, Hadassah Medical Organization (HMO)
Prof. Eyal Mishani
Born in Israel in 1963, married with two children. In 1990, I received my Bachelor’s degree in
Chemistry from Tel Aviv University with Distinction. Subsequently, I started direct courses towards
Ph.D. studies in the field of Organic Fluorine Chemistry. In 1994, I received my Ph.D. degree With
Distinction from Tel Aviv University. From 1994-1996, I completed my post-doctoral fellowship at
Washington University, St. Louis, MO, in the field of PET molecular imaging.
During my postdoctoral fellowship, I designed the PET/Radiochemistry Laboratory at
Hadassah/Hebrew University Hospital in Israel. Beginning of 1997, I returned to Israel to establish
the first PET Cyclotron facility in Israel in which I presently serve as Director of the Unit. Upon
my return to Israel, I pioneered the production and distribution of PET radiopharmaceuticals which
completely transformed the clinical diagnostic approach in Israel. At that time, together with the
Health Ministry, I established the guidelines for FDG production. In 2002, I founded a start-up
company, TK-Signal, engaged in molecular imaging of cancer, with a multi-million dollar
investment by leading investment funds. In 2010, I completed the installation of a second Cyclotron
and a microPET/CT (the first in Israel) at Hadassah Hospital. From 2012 until 2017, I served as an
expert in the field of quality management in Nuclear Medicine at the International Atomic Energy
Agency (IAEA). In 2013, I signed a long-term licensing agreement with a European based
company on a novel cardiac imaging technology developed in my lab. In 2016, I finished the
construction of a GMP-radiopharmacy at Hadassah. In 2022, in a pioneering step, and after a 6-year
endeavor, I have completed the registration of a radio-drug, LuNET-SRY, for therapy of
neuroendocrine tumors. LuNET-SRY is the first locally manufactured radiopharmaceutical
registered in Israel.
In 2012, I appointed as a full Professor at Hadassah/Hebrew University Hospital. I am a member of
the editorial board of Nuclear Medicine and Biology (the official journal of the International Society
of Radiopharmaceutical Sciences) and I serve as the International Associate Editor of Molecular
Imaging and Biology (the official journal of the Society of Molecular Imaging). During 2011-2013,
I served as the director at large of the International Society of Radiopharmaceutical Sciences. In
2016, I appointed as a visiting professor at Chulabhron Royal Academy Thailand in the field of
Radiopharmacy.
Throughout the ensuing years, I served as reviewer of several journals such as Journal of Medicinal
Chemistry, Journal of Nuclear Medicine, Journal of Labeled Compounds and
Radiopharmaceuticals, Applied Radiation and Isotopes, etc.
In mid-2014, I appointed as director of the R&D division at Hadassah Medical Organization, the
General Director of the Research Fund of the Hadassah Medical Organization (RFHMO) and a
board member of Hadassit, the technology transfer company of Hadassah. I established the research
fund as an independent legal entity and today there are over than 300 research employees with
multi-million dollars funds for research projects. In 2019, I established the Wohl translational
Medicine research Center and in 2020, I established the Organoid research center both in Hadassah.
My main research aim is to develop molecular imaging methodologies to explore the in–vivo
mechanism of various biochemical processes under normal and pathological conditions and
translate them into imaging of diseases. In this context, I have pioneered several basic and
comprehensive research projects encompassing various fields of nuclear medicine molecular
imaging.
I have more than 140 peer-reviewed publications and six patents in the field of imaging protein
tyrosine kinases, AR in cancer and MPI.
During the years, I have served as mentor to seven Ph.D. and to five M.Sc. students in the field of
molecular imaging and I have formulated a special course in this particular field at the School of
Pharmacy of the Hebrew University.
I served as consultant to several companies and institutions such as: Rotem Industries, Inc., Israel,
in the field of radiation safety; Soreq Nuclear Research Center, Israel, in the field of
radiopharmaceuticals; Pain Therapeutics, Inc., USA, in the field of radiopharmaceuticals for
therapy; Chulabhron Hospital, Thailand, in the field of Radiopharmaceutical production; Synektik
LTD, Poland, in the field of radiopharmaceutical production; European Medical Center, Russia,
designing and constructing cyclotron and GMP radiopharmacy site.